Advanced search
Publication Cover
Emerging Microbes & Infections Volume 11, 2022 - Issue 1
Submit an article Journal homepage
5,055
Views
24
CrossRef citations to date
0
Altmetric
Coronaviruses

Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis

Su-Yeon Yua Division for Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Republic of KoreaORCID Iconhttps://orcid.org/0000-0001-5488-5068View further author information
ORCID Icon,
Dae-Hyup Koha Division for Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Republic of KoreaORCID Iconhttps://orcid.org/0000-0003-2720-4006View further author information
ORCID Icon,
Miyoung Choia Division for Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Republic of KoreaORCID Iconhttps://orcid.org/0000-0002-2424-9965View further author information
ORCID Icon,
Seungeun Ryooa Division for Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Republic of KoreaORCID Iconhttps://orcid.org/0000-0002-0604-5141View further author information
ORCID Icon,
Kyungmin Huhb Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaORCID Iconhttps://orcid.org/0000-0002-5140-3964View further author information
ORCID Icon,
Joon Sup Yeomc Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of KoreaORCID Iconhttps://orcid.org/0000-0001-8940-7170View further author information
ORCID Icon &
Young Kyung Yoond Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of KoreaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8435-935XView further author information
ORCID Icon show all
Pages 1154-1165 | Received 19 Jan 2022, Accepted 25 Mar 2022, Published online: 18 Apr 2022

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Robert Flisiak, Marta Flisiak-Jackiewicz, Piotr Rzymski & Dorota Zarębska-Michaluk. (2023) Tocilizumab for the treatment of COVID-19. Expert Review of Anti-infective Therapy 21:8, pages 791-797.
Read now
E. Falcinelli, E. Petito & P. Gresele. (2022) The role of platelets, neutrophils and endothelium in COVID-19 infection. Expert Review of Hematology 15:8, pages 727-745.
Read now

Articles from other publishers (22)

Carolin Christina Drost, Alexandros Rovas, Irina Osiaevi, Klaus Schughart, Alexander Lukasz, Wolfgang A. Linke, Hermann Pavenstädt & Philipp Kümpers. (2024) Interleukin-6 drives endothelial glycocalyx damage in COVID-19 and bacterial sepsis. Angiogenesis.
Crossref
Nan Xiong & Qiangming Sun. (2024) Identifying COVID‐19 subtypes by single‐sample gene set enrichemnt analysis and providing guidance for sensitive drug selection. Journal of Medical Virology 96:3.
Crossref
Ohoud Aljuhani, Khalid Al Sulaiman, Ghazwa B. Korayem, Ali F. Altebainawi, Samiah Alsohimi, Rahaf Alqahtani, Saeedah Alfaifi, Aisha Alharbi, Azzah AlKhayrat, Ahmed Hattan, Meshal Albassam, Omar A. Almohammed, Atheer Alkeraidees, Dhay A. Alonazi, Weam F. Alsalman, Ghaliah Aldamegh, Rasha Alshahrani & Ramesh Vishwakarma. (2024) The association between tocilizumab therapy and the development of thrombosis in critically ill patients with COVID-19: a multicenter, cohort study. Scientific Reports 14:1.
Crossref
Beatriz Marinho Silva Romão, Felipe Vieira Duval, Elisângela Costa Lima, Fabrício Alves Barbosa da Silva & Guacira Correa de Matos. (2024) Detection of potential safety signals related to the use of remdesivir and tocilizumab in the COVID era during pregnancy, resorting to open data from the FDA adverse event reporting system (FAERS). Frontiers in Pharmacology 15.
Crossref
Alessio Simonetti, Antonio Restaino, Evelina Bernardi, Ottavia Marianna Ferrara, Stella Margoni, Antonio Maria D’Onofrio, Federica Ranieri, Delfina Janiri, Vincenzo Galluzzo, Matteo Tosato, Georgios D. Kotzalidis, Francesco Landi & Gabriele Sani. (2024) Effect of Anti-Interleukin-6 Agents on Psychopathology in a Sample of Patients with Post-COVID-19 Syndrome: An Observational Study. Brain Sciences 14:1, pages 47.
Crossref
Amy L. Lightner, Vikram Sengupta, Sascha Qian, John T. Ransom, Sam Suzuki, David J. Park, Timothy I. Melson, Brian P. Williams, James J. Walsh & Mustafa Awili. (2023) Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19. CHEST 164:6, pages 1444-1453.
Crossref
Marina Yamashita, Mamiko Takayasu, Hiroshi Maruyama & Kouichi Hirayama. (2023) The Immunobiological Agents for Treatment of Antiglomerular Basement Membrane Disease. Medicina 59:11, pages 2014.
Crossref
Zhiping Qin, Yongbiao Li, Wenjing Sun, Yangyang Lu, Nana Zhang, Rongfei Yang, Yiting Liu, Li Tang & Qingshan Liu. (2023) Effect of anti-inflammatory drugs on the storm of inflammatory factors in respiratory tract infection caused by SARS-CoV-2: an updated meta-analysis. Frontiers in Public Health 11.
Crossref
Rong Peng, Ting Yang, Yu Tong, Ji Wang, Hui Zhou, Minglong Yang, Junchen Zhu, Lijun Yang, Zheng Shi & Ya Liu. (2023) Efficacy and safety of interleukin-6 receptor antagonists in adult patients admitted to intensive care unit with COVID-19: A systematic review and meta-analysis of randomized controlled trials. Preventive Medicine Reports 34, pages 102276.
Crossref
Harsha Dissanayake. (2023) COVID-19 and metabolic syndrome. Best Practice & Research Clinical Endocrinology & Metabolism 37:4, pages 101753.
Crossref
Guilherme Pasetto Fadanni & João Batista Calixto. (2023) Recent progress and prospects for anti-cytokine therapy in preclinical and clinical acute lung injury. Cytokine & Growth Factor Reviews 71-72, pages 13-25.
Crossref
Lina Ghosn, Rouba Assi, Theodoros Evrenoglou, Brian S Buckley, Nicholas Henschke, Katrin Probyn, Carolina Riveros, Mauricia Davidson, Carolina Graña, Hillary Bonnet, Alexander Jarde, Camila Ávila, Camilla Hansen Nejstgaard, Sonia Menon, Gabriel Ferrand, Philipp Kapp, Claudia Breuer, Christine Schmucker, Yanina Sguassero, Thu Van Nguyen, Declan Devane, Joerg J Meerpohl, Gabriel Rada, Asbjørn Hróbjartsson, Giacomo Grasselli, David Tovey, Philippe Ravaud, Anna Chaimani & Isabelle Boutron. (2023) Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database of Systematic Reviews 2023:6.
Crossref
Muhammad Zeeshan Munir, Amer Hayat Khan & Tahir Mehmood Khan. (2023) Clinical Disease Characteristics and Treatment Trajectories Associated with Mortality among COVID-19 Patients in Punjab, Pakistan. Healthcare 11:8, pages 1192.
Crossref
Mardheya Al. Kharusi, Naffesa Al Sheikh, Maiya Alhajri, Seif Ali Al. Mandhri, El-Sayed Khafagy, Ehssan H. Moglad, Hadil Faris Alotaibi & Wael A. H. Hegazy. (2023) A Prospective Cohort Study of COVID-19: Evaluation of the Early Role of IL-1 and IL-6 Antagonists in Improving the Outcome of the Illness and Reduction in the Risk of Death. Healthcare 11:7, pages 1025.
Crossref
Nelson Luis Cahuapaza-Gutierrez & Tsuriel Sofía Campos-Escalante. (2023) Miocarditis por SARS-CoV-2. Una breve revisión. REC: CardioClinics 58:2, pages 129-137.
Crossref
Al Shaimaa Ibrahim Rabie, Hager Salah, Amira S. A. Said, Ahmed Hassan Shaaban, Lamya Mohamed Abdou, Doaa Mahmoud Khalil, Zelal Kharaba, Hala Afifi, Mahmoud R. Sofy, Eman M. I. Youssef, Eman S. M. Bayoumy & Raghda R. S. Hussein. (2023) Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection. Healthcare 11:4, pages 607.
Crossref
Miyoung Choi, Hyeon-Jeong Lee, Su-Yeon Yu, Jimin Kim, Jungeun Park, Seungeun Ryoo, Inho Kim, Dong Ah Park, Young Kyung Yoon, Joon-Sung Joh, Sunghoon Park, Ki Wook Yun, Chi-Hoon Choi, Jae-Seok Kim, Sue Shin, Hyun Kim, Kyungmin Huh, In-Seok Jeong, Soo-Han Choi, Sung Ho Hwang, Hyukmin Lee, Dong Keon Lee, Hwan Seok Yong & Ho Kee Yum. (2023) Two Years of Experience and Methodology of Korean COVID-19 Living Clinical Practice Guideline Development. Journal of Korean Medical Science 38:23.
Crossref
C. Lefèvre, A. Plocque, M. Tran, M. Creux & F. Philippart. (2023) Inhibiteurs du récepteur de l’IL-6 dans le traitement de la COVID-19 : que savons-nous ?. Revue des Maladies Respiratoires 40:1, pages 24-37.
Crossref
E. V. Tavlueva, E. V. Zernova, M. P. Kutepova, N. E. Kostina, V. S. Lesina, D. R. Mould, K. Ito, A. V. Zinchenko, A. N. Dolgorukova, M. V. Nikolskaya, M. S. Lemak, O. V. Filon & M. Yu. Samsonov. (2022) CHARACTERISTICS OF OLOKIZUMAB PHARMACOKINETICS IN PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19. Pharmacy & Pharmacology 10:5, pages 460-471.
Crossref
Fatma Haddad, Ghadeer Dokmak & Rafik Karaman. (2022) A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. Life 12:11, pages 1758.
Crossref
Mohammad Mahdi Rezaei Tolzali, Maryam Noori, Pourya Shokri, Shayan Rahmani, Shokoufeh Khanzadeh, Seyed Aria Nejadghaderi, Asra Fazlollahi, Mark J. M. Sullman, Kuljit Singh, Ali‐Asghar Kolahi, Shahnam Arshi & Saeid Safiri. (2022) Efficacy of tocilizumab in the treatment of COVID‐19: An umbrella review. Reviews in Medical Virology 32:6.
Crossref
Tarani Kanta Barman, Amit K. Singh, Jesse L. Bonin, Tanvir Noor Nafiz, Sharon L. Salmon & Dennis W. Metzger. (2022) Lethal synergy between SARS-CoV-2 and Streptococcus pneumoniae in hACE2 mice and protective efficacy of vaccination. JCI Insight 7:11.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.